Biocompatibility of icodextrin

Kidney International, Supplement

Volumn 62, Issue 81, 2002, Pages

  Cooker, Laurinda A ^a   Holmes, Clifford J ^a   Hoff, Catherine M ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

APD; CAPD; Dialysate; Membrane permeability; Peritoneal cavity homeostasis; Renal replacement therapy; Ultrafiltration

Indexed keywords

ANTIGEN; CARBONYL DERIVATIVE; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; ICODEXTRIN; PLASMINOGEN; PROSTAGLANDIN E2; PROTEIN; ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLUCAN;

BIOCOMPATIBILITY; CONTROLLED STUDY; DEGRADATION; DIALYSIS MEMBRANE; GLYCATION; HUMAN; HYPEROSMOLARITY; KIDNEY TRANSPLANTATION; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PH; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN SYNTHESIS; REVIEW; ULTRAFILTRATION; METABOLISM; OSMOTIC PRESSURE; PERITONEUM;

DIALYSIS SOLUTIONS; GLUCANS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OSMOTIC PRESSURE; PERITONEAL DIALYSIS; PERITONEUM;

EID: 0036379655     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.62.s81.6.x     Document Type: Review

References (103)

1. NAGY J: Peritoneal membrane morphology and function. Kidney Int 50:2-11, 1996
2. HOLMES CJ: Peritoneal host defense mechanisms in peritoneal dialysis. Kidney Int 46(Suppl 48):S58-S70, 1994
3. TOPLEY N: The host's initial response to peritoneal infection: The pivotal role of the mesothelial cell. Perit Dial Int 15:116-117, 1995
4. TOPLEY N, MACKENZIE R, WILLIAMS J: Macrophages and mesothelial cells in bacterial peritonitis. Immunobiology 195:563-573, 1996
5. BRULEZ HF, VERBRUGH HA: First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 15(Suppl 7):S24-S33, 1995
6. SITTER T, TOET K, QUAX P, KOOISTRA T: Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator. Kidney Int 55:120-129, 1999
7. HOLMDAHL L, FALKENBERG M, IVARSSON M, RISBERG B: Plasminogen activators and inhibitors in peritoneal tissue. APMIS 105:25-30, 1997
8. SITTER T, TOET K, FRICKE H, et al: Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators. Am J Physiol 271:R1256-R1263, 1996
9. VAN HINSBERGH VW, KOOISTRA T, SCHEFFER M, et al: Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood 75:1490-1497, 1990
10. MARTIN J, YUNG S, ROBSON R, et al: Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int 20:524-533, 2000
11. YUNG S, DAVIES M: Response of the human peritoneal mesothelial cell to injury: An in vitro model of peritoneal wound healing. Kidney Int 54:2160-2169, 1998
12. BASOK A, SHNAIDER A, MAN L, et al: CD40 is expressed on human peritoneal mesothelial cells and upregulates the production of interleukin-15 and RANTES. J Am Soc Nephrol 12:695-702, 2001
13. DOUVDEVANI A, RAPOPORT J, KONFORTY A, et al: Human peritoneal mesothelial cells synthesize IL-1 alpha and beta. Kidney Int 46: 993-1001, 1994
14. TOPLEY N, BROWN Z, JÖRRES A, et al: Human peritoneal mesothelial cells synthesize IL-8: Synergistic induction by interleukin-1β and tumor necrosis factor α. Am J Pathol 142:1876-1886, 1993
15. TOPLEY N, JÖRRES A, LUTTMANN W, et al: Human peritoneal mesothelial cells synthesize IL-6: Induction by IL-1β and TNFα. Kidney Int 43:226-233, 1993
16. LEE SK, KIM B, YANG W, et al: High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int 60:55-64, 2001
17. LIBEREK T, TOPLEY N, LUTTMANN W, WILLIAMS JD: Adherence of neutrophils to human peritoneal mesothelial cells: Role of intercellular adhesion molecule-1. J Am Soc Nephrol 7:208-217, 1996
18. 2 synthesis in human peritoneal mesothelial cells: Role of hyperosmolarity. J Am Soc Nephrol 9:2005-2012, 1998
19. CHEN JY, YANG A, LIN Y, et al: Absence of modulating effects of cytokines on antioxidant enzymes in peritoneal mesothelial cells. Perit Dial Int 17:455-466, 1997
20. STYLIANOU E, JENNER LA, DAVIES M, et al: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 37:1563-1570, 1990
21. OFFNER FA, FEICHTINGER H, STADLMANN S, et al: Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol 148:1679-1688, 1996
22. YANG WS, KIM BS, LEE SK, et al: Interleukin-1beta stimulates the production of extracellular matrix in cultured human peritoneal mesothelial cells. Perit Dial Int 19:211-220, 1999
23. HA H, YU MR, LEE HB: High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 59:463-470, 2001
24. YUNG S, THOMAS G, STYLIANOU E, et al: Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. Am J Pathol 146:520-529, 1995
25. YUNG S, COLES GA, DAVIES M: IL-1β, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: Relevance to peritonitis in CAPD. Kidney Int 50:1337-1343, 1996
26. LAI KN, LI F, LAN H, et al: Expression of aquaporin-1 in human peritoneal mesothelial cells and its upregulation by glucose in vitro. J Am Soc Nephrol 12:1036-1045, 2001
27. SCHROPPEL B, FISCHEREDER M, WIESE P, et al: Expression of glucose transporters in human peritoneal mesothelial cells. Kidney Int 53:1278-1287, 1998
28. DOBBIE J: Ultrastructure and pathology of the peritoneum in peritoneal dialysis, in The Textbook of Peritoneal Dialysis, edited by GOKAL R, NOLPH K, Dordrecht, Kluwer Academic Publishers, 1994, pp 17-44
29. KREDIET RT: The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 55:341-356, 1999
30. CHEN CJ, MOBERLY JB, MARTIS L: New developments in peritoneal dialysis solutions. Adv Perit Dial 14:116-119, 1998
31. CHUNG SH, STENVINKEL P, BERGSTRÖM J, LINDHOLM B: Biocompatibility of new peritoneal dialysis solutions: What can we hope to achieve? Perit Dial Int 20(Suppl 5):S57-S67, 2000
32. GOKAL R: Newer peritoneal dialysis solutions. Adv Ren Replace Ther 7:302-309, 2000
33. HOLMES C, SHOCKLEY T: Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 20(Suppl 2):S27-S31, 2000
34. JONES S, HOLMES C, KREDIET R, et al: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 59:1529-1538, 2001
35. MISTRY CD, GOKAL R, PEERS E: A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46:496-503, 1994
36. MISTRY CD, MALLICK NP, GOKAL R: Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 2:178-182, 1987
37. ALSOP R: History, chemical, and pharmaceutical development of icodextrin. Perit Dial Int 14(Suppl 2):S5-S12, 1994
38. DOBBIE JW, LLOYD J, GALL C: Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 6:3-12, 1990
39. DI PAOLO N, SACCHI G: Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int 9:41-45, 1989
40. GOTLOIB L, BAR-SELLA P, SHOSTAK A: Reduplicated basal lamina of small venules and mesothelium of human peritoneal membrane. Perit Dial Bull 5:212-215, 1985
41. HONDA K, NITTA K, HORITA S, et al: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72:171-176, 1996
42. KANG DH, HONG Y, LIM H, et al: High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: Effect of cytokine costimulation. Perit Dial Int 19:221-230, 1999
43. WANG T, CHEN YG, YE RG, et al: Effect of glucose on TGF-β expression in peritoneal mesothelial cells. Adv Perit Dial 11:7-10, 1995
44. KUMANO K, SCHILLER B, HJELLE J, MORAN J: Effects of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. Blood Purif 14:165-169, 1996
45. KUMANO K, SHIMODA M, HYODO T, SAKAI T: The role of TGF-beta in growth inhibition of peritoneal mesothelial cells in high-glucose dialysate. Perit Dial Int 15(Suppl 7):S93-S95, 1995
46. MARGETTS PJ, KOLB M, GALT T, et al: Gene transfer of transforming growth factor-β1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol 12:2029-2039, 2001
47. ITO T, YORIOKA N, YAMAMOTO M, et al: Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol 11:1969-1979, 2000
48. HA H, YU MR, CHOI HN, et al: Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 20(Suppl 5):S10-S18, 2000
49. SHOSTAK A, WAJSBROT V, GOTLOIB L: High glucose accelerates the life cycle of the in vivo exposed mesothelium. Kidney Int 58: 2044-2052, 2000
50. LAMEIRE N, BIESEN WV, VANHOLDER R: Consequences of using glucose in peritoneal dialysis fluid. Semin Dial 11:271-275, 1998
51. KUBOSHIMA S, OGIMOTO G, SAKURADA T, et al: Hyperosmotic stimuli induces recruitment of aquaporin-1 to plasma membrane in cultured rat peritoneal mesothelial cells. Adv Perit Dial 17:47-52, 2001
52. HONDA K, NITTA K, HORITA S, et al: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 14:1541-1549, 1999
53. NISHIDA Y, SHAO J, KIRIBAYASHI K, et al: Advanced glycation end-products reduce the viability of human peritoneal mesothelial cells. Nephron 80:477-478, 1998
54. MIYATA T, HORIE K, UEDA Y, et al: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425-435, 2000
55. SITTER T, MANDL-WEBER S, WORNLE M, et al: D-glucose increases the synthesis of tissue-type plasminogen activator (t-PA) in human peritoneal mesothelial cells. Thromb Haemost 82:1171-1176, 1999
56. BAJO MA, SELGAS R, CASTRO MA, et al: Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int 20:742-747, 2000
57. JÖRRES A, GAHL GM, TOPLEY N, et al: In vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate buffered and glucose polymer based solutions. Nephrol Dial Transplant 9: 785-790, 1994
58. DE FIJTER CWH, VERBRUGH HA, OE LP, et al: Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 4:411-418, 1993
59. THOMAS S, SCHENK U, FISCHER F, et al: In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis 29:246-253, 1997
60. LIBEREK T, TOPLEY N, MISTRY CD, et al: Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 13:104-111, 1993
61. STEINHAUER HB, SCHOLLMEYER P: Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 29:584-590, 1986
62. KNUDSEN PJ, DINARELLO CA, STROM TB: Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immun 137:3189-3194, 1986
63. MARPLES D: Aquaporins: Roles in renal function and peritoneal dialysis. Perit Dial Int 21:212-218, 2001
64. PLUM J, LORDNEJAD M, GRABENSEE B: Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 54:224-235, 1998
65. GOTLOIB L, SHOSTAK A, WAJSBROT V: Effects of osmotic agents upon the in vivo exposed mesothelial monolayer. Perit Dial Int 20(Suppl 2):S11-S14, 2000
66. POSTHUMA N, VERBRUGH HA, DONKER AJ, et al: Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 20:174-180, 2000
67. POSTHUMA N, TER WEE P, DONKER AJ, et al: Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 19:334-342, 1999
68. WIESLANDER AP, NORDIN MK, KJELLSTRAND PTT, BOBERG UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 40:77-79, 1991
69. MARTIS L, HENDERSON L: Impact of terminal heat sterilization on the quality of peritoneal dialysis solutions. Blood Purif 15:54-60, 1997
70. WIESLANDER A, LINDÉN T: Glucose degradation and cytotoxicity in PD fluids. Perit Dial Int 16:114-118, 1996
71. KJELLSTRAND P, MARTINSON E, WIESLANDER A, HOLMQUIST B: Development of toxic degradation products during heat sterilisation of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature. Perit Dial Int 15:26-32, 1995
72. WIESLANDER A, ANDRÉN A, NILSSON-THORELL C, et al: Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 15:348-352, 1995
73. WITOWSKI J, KORYBALSKA K, WISNIEWSKA J, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 11:729-739, 2000
74. THORNALLEY PJ, WESTWOOD M, LO TW, MCLELLAN AC: Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol 112:24-31, 1995
75. LINDEN T, FORSBÄCK G, DEPPISCH R, et al: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 18:290-293, 1998
76. NIWA H, TAKEDA A, WAKAI M, et al: Accelerated formation of N epsilon-(carboxymethyl) lysine, an advanced glycation end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons. Biochem Biophys Res Commun 248:93-97, 1998
77. MIYATA T, VAN YPERSELE DE STRIHOU C, KUROKAWA K, BAYNES JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
78. UEDA Y, MIYATA T, GOFFIN E, et al: Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 58:2518-2524, 2000
79. COOKER L, CHOO C, LUNEBURG P, et al: Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial 15:17-20, 1999
80. NILSSON-THORELL CB, MUSCALU N, ANDREN AHG, et al: Heat sterilisation of peritoneal dialysis gives rise to aldehydes. Perit Dial Int 13:208-213, 1993
81. WITOWSKI J, BENDER T, GAHL G, et al: Glucose degradation products and peritoneal membrane function. Perit Dial Int 21:201-205, 2001
82. WIESLANDER AP, NORDIN MK, MARTINSON E, et al: Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 39:343-348, 1993
83. MIYATA T, KUROKAWA K: Carbonyl stress: Increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia. Int J Artif Organs 22:195-198, 1999
84. MIYATA T, INAGI R, IIDA Y, et al: Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 93:521-528, 1994
85. LU M, KUROKI M, AMANO S, et al: Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219-1224, 1998
86. SATOH H, TOGO M, HARA M, et al: Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun 239:111-115, 1997
87. COMBET S, MIYATA T, MOULIN P, et al: Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 11:717-728, 2000
88. MIYATA T, DEVUYST O, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61:375-386, 2002
89. NAKAYAMA M, KAWAGUCHI Y, YAMADA K, et al: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51:182-186, 1997
90. LAMB EJ, CATTELL WR, DAWNAY AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 47:1768-1774, 1995
91. BOULANGER E, WAUTIER M-P, WAUTIER J-L, et al: AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61:148-156, 2002
92. DAWNAY A, MILLAR D: Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 17:52-58, 1997
93. BARRE D, CHEN C, COOKER L, MOBERLY J: Decreased in vitro formation of AGEs with Extraneal™ solution compared to dextrose-containing PD solutions. Adv Perit Dial 15:12-16, 1999
94. TOMO T, SHIBATA T, NASU M: Maillard reaction and AGE formation in glucose and polyglucose dialysis solutions. Perit Dial Int 19:274-277, 1999
95. POSTHUMA N, TER WEE PM, NIESSEN H, et al: Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Perit Dial Int 21:43-51, 2001
96. LEE JH, REDDY DK, SARAN R, et al: Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 20:643-651, 2000
97. HO-DAC-PANNEKEET MM, WEISS MF, DE WAART DR, et al: Analysis of non enzymatic glycosylation in vivo: Impact of different dialysis solutions. Perit Dial Int 19(Suppl 2):S68-S74, 1999
98. HEIMBÜRGER O, WANG T, LINDHOLM B: Alteration in water and solute transport with time on peritoneal dialysis. Perit Dial Int 19(Suppl):S83-S90, 1999
99. REICHEL W, SCHULZE B, DIETZE J, MENDE W: A case of sterile peritonitis associated with icodextrin solution. Perit Dial Int 21: 414-415, 2001
100. HERRING P, BRAUSE M, PLUM J, GRABENSEE B: Peritoneal reaction to icodextrin in a female patient on CAPD. Perit Dial Int 21:321-322, 2001
101. PINEROLO MC, PORRI M, D'AMICO G: Recurrent sterile peritonitis at onset of treatment with icodextrin solution. Perit Dial Int 19: 491-492, 1999
102. DEL ROSSO G, DI LIBERATO L, PERILLI A, et al: A new form of acute adverse reaction to icodextrin in a peritoneal dialysis patient. Nephrol Dial Transplant 15:927-928, 2000
103. WILLIAMS JD, CRAIG KJ, TOPLEY N, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470-479, 2002